Monopar Therapeutics reports Q4 2024 net loss $10.9M; cash $60.2M; ALXN1840 NDA planned early 2026

Monopar Therapeutics

Q4 2024 net loss $10.9M ($2.23/share) vs $1.8M ($0.60/share) in Q4 2023.
FY2024 net loss $15.6M ($4.11/share) vs $8.4M ($3.04/share) in FY2023; R&D expenses rose to $13.0M from $5.6M.
Cash and short-term investments $60.2M at Dec 31, 2024; expects runway through Dec 31, 2026.
Plan to submit NDA for ALXN1840 (Wilson disease) to FDA in early 2026.
Raised net proceeds ~$55M from Q4 2024 financings; MNPR-101-Lu Phase 1a dosed first patient in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.